Patient-reported Outcomes with Hyaluronidase-facilitated Subcutaneous Immunoglobulin 10% Maintenance Therapy for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (P9-11.002)

To determine the effect of facilitated subcutaneous immunoglobulin (fSCIG; human immunoglobulin G 10% with recombinant human hyaluronidase) on patient-reported outcomes (PROs) in a Phase 3, randomized, placebo-controlled, double-blind, multicenter study (ADVANCE-CIDP 1; NCT02549170).